Endometrial cancer trials in France

In France 47 Also abroad 395

47 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Where
Angers, Besancon Cedex, Caen Cedex 5, Le Mans, Marseille, Paris, Saint-Herblain Cedex, Strasbourg Cedex 2, Vandoeuvre-lès-nancy
Age
18 years and over
People
480 worldwide
Run by
BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00
Phase 1Taking people
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Where
Lyon, Nice Cedex 2, Rennes Cedex, Saint-Herblain Cedex, Strasbourg Cedex 2, Villejuif
Age
18 years and over
People
156 worldwide
Run by
Context Therapeutics Inc.
See details and how to joinNCT06515613 · EU 2025-523968-20-00
Phase 3Taking people
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Where
Bordeaux, Caen Cedex 5, Lyon, Marseille, Paris, Plérin, Saint-Cloud, Saint-Herblain Cedex, Toulouse Cedex 9
Age
18 years and over
People
1,123 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00
Phase 1/2Taking people
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Where
Lyon, Marseille, Paris
Age
18 years and over
People
616 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07020221
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Lyon, Saint-Herblain Cedex, Toulouse Cedex 9
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bordeaux, Brest, Lille, Montpellier, Pierre-Bénite, Villejuif
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Where
Angers, Bayonne, Bordeaux, Brest, Clermont-Ferrand, Dijon, Grenoble, Montpellier, Nancy, Orléans, Reims, Strasbourg, Suresnes
Age
18 years and over
People
660 worldwide
Run by
Genmab
See details and how to joinNCT07166094
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Pierre-Bénite
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 3Taking people
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Where
Avignon Cedex 9, Besancon Cedex, Bordeaux, Brest, Caen Cedex 5, Clermont Ferrand Cedex1, Lille, Montpellier, Nantes Cedex 2, Nice Cedex 2, Pierre-Bénite, Rennes Cedex, Strasbourg Cedex 2, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
710 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07022483 · EU 2024-519444-33-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Where
Bordeau, Marseille, Paris, Poitiers, Villejuif
Age
18 years and over
People
542 worldwide
Run by
Artios Pharma Ltd
See details and how to joinNCT04657068
Phase 2Taking people
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Where
Lille, Lyon, Paris, Toulouse, Villejuif
Age
18 years and over
People
393 worldwide
Run by
Canadian Cancer Trials Group
See details and how to joinNCT05640999
Phase 3Taking people
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Where
Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Lyon, Montpellier Cedex 5, Nice Cedex 2, Paris, Plérin, Poitiers, Saint-Herblain Cedex, Toulouse Cedex 9
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Pierre-Bénite
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
Phase 3Taking people
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Where
Besancon Cedex, Bordeaux, Lyon, Marseille, Montpellier Cedex 5, Nice Cedex 2, St Herblain, Strasbourg, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
316 worldwide
Run by
Leiden University Medical Center
See details and how to joinNCT05255653 · EU 2023-503267-42-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Bordeaux, Clermont-Ferrand, Lyon, Nîmes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Angers, Limoges Cedex I, Strasbourg Cedex 2, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
Phase 1/2Taking people
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Where
Bordeaux, Caen Cedex 5, Dijon, Lyon, Nice Cedex 2, Pierre-Bénite, Villejuif Cedex
Age
18 years and over
People
890 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00
Phase 1/2Taking people
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Where
Bordeaux, Caen Cedex 5, Dijon, Pierre-Bénite, Villejuif
Age
18 years and over
People
612 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT04590326 · EU 2022-501904-83-00
No phaseTaking people
Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer
Where
Besançon, Caen, Clermont-Ferrand, Lyon, Paris, Plérin, Saint-Cloud, Saint-Etienne, Strasbourg, Villejuif
Age
18 years and over
People
268
Run by
Centre Francois Baclesse
See details and how to joinNCT06553612
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Bordeaux, Lyon, Suresnes
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, Strasbourg
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Lyon, Paris, Saint-Herblain, Villejuif
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 1/2Taking people
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Where
Lyon, Saint-Herblain, Villejuif
Age
18 years and over
People
47 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07213609